Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.55
- Piotroski Score 6.00
- Grade Outperform
- Symbol (TAK)
- Company Takeda Pharmaceutical Company Limited
- Price $14.21
- Changes Percentage (-2.27%)
- Change -$0.33
- Day Low $14.18
- Day High $14.44
- Year High $15.47
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 03/27/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.29
- Trailing P/E Ratio 46.45
- Forward P/E Ratio 46.45
- P/E Growth 46.45
- Net Income $144.07 B
Income Statement
Quarterly
Annual
Latest News of TAK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Qatar Airways buys into Virgin Australia, raising the stakes against Qantas
By Praveen Menon and Himanshi AkhandSYDNEY (Reuters) -Qatar Airways will buy a 25% stake in Virgin Australia from U.S. private equity firm Bain Capital, posing a tougher contest for Qantas Airways tha...
By Reuters | 39 minutes ago -
AT&T sells 70% stake in DirecTV to TPG for $7.6 billion
AT&T is selling its 70% stake in DirecTV to TPG for $7.6 billion, as part of efforts to focus on core operations. AT&T will receive an initial payment of $2 billion in 2025, with additional payments u...
By CNBC | 17 hours ago -
Mark Rutte takes charge of Nato at a perilous moment for Ukraine
Mark Rutte, a seasoned Dutch politician, takes over as Nato secretary general during a crucial time for Ukraine. With extensive coalition-building experience, Rutte aims to address challenges such as ...
By The Guardian | 17 hours ago
